Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

The wildly popular and effective GLP-1 drugs Mounjaro from Eli Lilly and Ozempic from Novo Nordisk are approved in the United ...

Rigel's Q2 results highlight soaring revenue and raised guidance for 2025. See more on RIGL stock's growth potential, ...

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...

Drugs to treat ADHD were linked to a reduced risk of suicidal behavior, substance misuse and criminality in the first research of its kind.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

The drugmaker is one step closer to breaking ground on over 200 acres of land in a Houston development that's seeking ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after reports of ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Eli Lilly and Company (NYSE: LLY) is one of the best upside stocks to invest in now. On August 11, Eli Lilly announced its ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...